Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is headquartered in Bordeaux, France.
तुलना करने के लिए मीट्रिक्स | AELIS | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधAELISपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −6.7x | −3.3x | −0.6x | |
PEG अनुपात | 0.37 | −0.06 | 0.00 | |
क़ीमत/बुक | 4.8x | 1.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 4.4x | 7.2x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 331.0% | 167.7% | 48.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 4.6% | 6.9% | अनलॉक करें |